Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hematopoietic stem cell transplantation for multiple sclerosis: current status and future challenges.

Paolo A Muraro1, Riccardo Cassiani Ingoni, Roland Martin

  • 1Neuroimmunology Branch, National Institute of Neurological Diseases and Stroke, National Institutes of Health, MSC1400 Bethesda, MD 20892-1400, USA.

Current Opinion in Neurology
|July 15, 2003
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Should autologous HSCT be a first-line option in highly active MS: YES.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Therapeutic immune tolerance for central nervous system autoimmune diseases - Prospects, challenges and pitfalls.

Seminars in immunology·2026
Same author

Distinct Clinico-pathogenic Subgroups in Pediatric Lyme Neuroborreliosis.

Open forum infectious diseases·2026
Same author

A tight match: comparing the effectiveness of immune reconstitution therapies for multiple sclerosis.

Brain : a journal of neurology·2026
Same author

Anoctamin-2-specific T cells link Epstein-Barr virus to multiple sclerosis.

Cell·2026
Same author

EBV infection and HLA-DR15 jointly drive multiple sclerosis by myelin peptide presentation.

Cell·2026

Hematopoietic stem cell transplantation shows promise in suppressing multiple sclerosis inflammation and offers potential for neural repair. Further clinical trials are needed to confirm long-term benefits and optimize treatment strategies.

Area of Science:

  • Neuroimmunology
  • Regenerative Medicine
  • Hematology

Background:

  • Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system.
  • Current MS therapies primarily focus on managing inflammation and symptoms, with limited options for repair.
  • Hematopoietic stem cells (HSCs) are being investigated for their immunomodulatory and regenerative potential in MS.

Purpose of the Study:

  • To review recent advancements in clinical trials of hematopoietic stem cell transplantation (HSCT) for multiple sclerosis.
  • To explore the potential of hematopoietic-derived precursors for neural repair in MS.
  • To summarize the current understanding of HSC migration, differentiation, and therapeutic applications in MS.

Main Methods:

  • Review of recent clinical trials and preclinical studies on HSCT for MS.

Related Experiment Videos

  • Analysis of data on HSC migration into the central nervous system (CNS).
  • Evaluation of evidence for HSC differentiation into neural and glial cells.

    • Main Results:

    • HSCT can effectively suppress the inflammatory component of MS.
    • HSCs demonstrate the ability to migrate into the CNS in both animal models and human patients.
    • HSCs possess the potential for neural and myelin repair, with observed differentiation into neural and glial markers.
    • Current clinical trials face challenges in evaluating long-term benefits due to heterogeneous regimens and patient selection.

    Conclusions:

    • HSCT is an experimental therapy with significant effects on MS inflammation.
    • Controlled clinical trials are underway to confirm the long-term efficacy of HSCT.
    • Future trials should focus on early-stage, high-risk patients and objective monitoring via MRI.
    • Advances in understanding HSC plasticity offer new avenues for remyelination and axonal repair strategies in MS.